Q2-osavuosiraportti
24 päivää sitten‧34 min
Tarjoustasot
Spotlight Stock Market SE
Määrä
Osto
16 601
Myynti
Määrä
43 471
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 171 | NRD | NON | ||
| 7 600 | NRD | AVA | ||
| 16 129 | AVA | NRD | ||
| 1 000 | AVA | NRD | ||
| 3 539 | AVA | NRD |
Ylin
0,58VWAP
Alin
0,556VaihtoMäärä
0,2 327 655
VWAP
Ylin
0,58Alin
0,556VaihtoMäärä
0,2 327 655
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Svenska Handelsbanken AB | 90 000 | 6 000 | +84 000 | 0 |
| Nordnet Bank AB | 100 191 | 72 892 | +27 299 | 5 000 |
| Carnegie Investment Bank AB | 7 128 | 0 | +7 128 | 0 |
| Skandinaviska Enskilda Banken AB | 32 | 0 | +32 | 0 |
| Nordea Bank Abp | 10 338 | 63 400 | −53 062 | 0 |
| Avanza Bank AB | 119 966 | 185 363 | −65 397 | 38 391 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Avanza Bank AB | 119 966 | 185 363 | −65 397 | 38 391 |
| Nordea Bank Abp | 10 338 | 63 400 | −53 062 | 0 |
| Skandinaviska Enskilda Banken AB | 32 | 0 | +32 | 0 |
| Carnegie Investment Bank AB | 7 128 | 0 | +7 128 | 0 |
| Nordnet Bank AB | 100 191 | 72 892 | +27 299 | 5 000 |
| Svenska Handelsbanken AB | 90 000 | 6 000 | +84 000 | 0 |
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 14.11. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 19.8. | |
| 2024 Yhtiökokous | 12.5. | |
| 2025 Q1-osavuosiraportti | 8.5. | |
| 2024 Q4-osavuosiraportti | 21.2. | |
| Merkintäoikeusanti | 3.1. |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
7.9.·AcuCort expands the organization with Business Development Director according to Linkedin https://cvformat.io/blog/business-development-director-job-overview- 28.8.·New orders, letters of intent and regulatory progress in interaction https://analystgroup.se/analyser/acucort-q2-25/
22.8.·Now the sales need to get going in earnest. However, it seems that there is a lack of information for doctors. Especially in general practice, there has been no information that the product is on the market. So GPs cannot prescribe it if they do not know the product exists. Bad, very bad PR…- 19.8. · Muokattu·There is a webcast about Q2 at 11am today, no registration required. There will be an opportunity to ask questions. https://www.youtube.com/live/sWHfe7XqRK8
19.8.·It sounds very good, if it weren't for the very boring/weak sales figures of 162 thousand kroner in the first half of the year. I still think it could be good, but my investment is based on hope and that I like that the product and company are simple - I don't think the numbers and the development speak much for it so far. - 19.8.·AcuCort publishes interim report for the second quarter of 2025 https://www.acucort.se/sv/acucort-publicerar-delarsrapport-for-andra-kvartalet-2025/19.8.·Acucort reports loss as expected - ongoing discussions with potential partners today at 08:40 ∙ Finwire Smallcap Life science company Acucort increases sales and losses in the second quarter. Revenue amounted to SEK 0.2 million (0). Operating profit was SEK -7.6 million (-3.8). Profit after tax was SEK -7.6 million (-3.8). Earnings per share were SEK -0.03 (-0.05). Cash and cash equivalents at the end of the period were SEK 32.4 million. "The second quarter of 2025 has been marked by clear and important steps forward in our international expansion. In May and June, we signed two strategic letters of intent regarding distribution agreements. The first was with Lunatus for the Middle East and the Gulf States and the second with Glenmark Pharmaceuticals for Germany and five additional European countries," CEO Jonas Jönmark says in the report. He is also raising the issue with the FDA regarding the iPSP application. "The FDA's response to our iPSP application was scheduled for the first quarter, but the process has been delayed due to internal organizational challenges at the agency. We have finally received their response and are now working to answer a number of questions that have been raised," says Jönmark. The Acucort CEO continues. "Looking ahead, we see several exciting opportunities. Our ongoing discussions with potential partners in both Europe and other parts of the world have intensified. At the same time, important efforts are underway in the regulatory area to secure long-term market access and build clinical credibility in all relevant markets."
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q2-osavuosiraportti
24 päivää sitten‧34 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 7.9.·AcuCort expands the organization with Business Development Director according to Linkedin https://cvformat.io/blog/business-development-director-job-overview
- 28.8.·New orders, letters of intent and regulatory progress in interaction https://analystgroup.se/analyser/acucort-q2-25/
- 22.8.·Now the sales need to get going in earnest. However, it seems that there is a lack of information for doctors. Especially in general practice, there has been no information that the product is on the market. So GPs cannot prescribe it if they do not know the product exists. Bad, very bad PR…
- 19.8. · Muokattu·There is a webcast about Q2 at 11am today, no registration required. There will be an opportunity to ask questions. https://www.youtube.com/live/sWHfe7XqRK819.8.·It sounds very good, if it weren't for the very boring/weak sales figures of 162 thousand kroner in the first half of the year. I still think it could be good, but my investment is based on hope and that I like that the product and company are simple - I don't think the numbers and the development speak much for it so far.
- 19.8.·AcuCort publishes interim report for the second quarter of 2025 https://www.acucort.se/sv/acucort-publicerar-delarsrapport-for-andra-kvartalet-2025/19.8.·Acucort reports loss as expected - ongoing discussions with potential partners today at 08:40 ∙ Finwire Smallcap Life science company Acucort increases sales and losses in the second quarter. Revenue amounted to SEK 0.2 million (0). Operating profit was SEK -7.6 million (-3.8). Profit after tax was SEK -7.6 million (-3.8). Earnings per share were SEK -0.03 (-0.05). Cash and cash equivalents at the end of the period were SEK 32.4 million. "The second quarter of 2025 has been marked by clear and important steps forward in our international expansion. In May and June, we signed two strategic letters of intent regarding distribution agreements. The first was with Lunatus for the Middle East and the Gulf States and the second with Glenmark Pharmaceuticals for Germany and five additional European countries," CEO Jonas Jönmark says in the report. He is also raising the issue with the FDA regarding the iPSP application. "The FDA's response to our iPSP application was scheduled for the first quarter, but the process has been delayed due to internal organizational challenges at the agency. We have finally received their response and are now working to answer a number of questions that have been raised," says Jönmark. The Acucort CEO continues. "Looking ahead, we see several exciting opportunities. Our ongoing discussions with potential partners in both Europe and other parts of the world have intensified. At the same time, important efforts are underway in the regulatory area to secure long-term market access and build clinical credibility in all relevant markets."
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market SE
Määrä
Osto
16 601
Myynti
Määrä
43 471
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 171 | NRD | NON | ||
| 7 600 | NRD | AVA | ||
| 16 129 | AVA | NRD | ||
| 1 000 | AVA | NRD | ||
| 3 539 | AVA | NRD |
Ylin
0,58VWAP
Alin
0,556VaihtoMäärä
0,2 327 655
VWAP
Ylin
0,58Alin
0,556VaihtoMäärä
0,2 327 655
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Svenska Handelsbanken AB | 90 000 | 6 000 | +84 000 | 0 |
| Nordnet Bank AB | 100 191 | 72 892 | +27 299 | 5 000 |
| Carnegie Investment Bank AB | 7 128 | 0 | +7 128 | 0 |
| Skandinaviska Enskilda Banken AB | 32 | 0 | +32 | 0 |
| Nordea Bank Abp | 10 338 | 63 400 | −53 062 | 0 |
| Avanza Bank AB | 119 966 | 185 363 | −65 397 | 38 391 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Avanza Bank AB | 119 966 | 185 363 | −65 397 | 38 391 |
| Nordea Bank Abp | 10 338 | 63 400 | −53 062 | 0 |
| Skandinaviska Enskilda Banken AB | 32 | 0 | +32 | 0 |
| Carnegie Investment Bank AB | 7 128 | 0 | +7 128 | 0 |
| Nordnet Bank AB | 100 191 | 72 892 | +27 299 | 5 000 |
| Svenska Handelsbanken AB | 90 000 | 6 000 | +84 000 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 14.11. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 19.8. | |
| 2024 Yhtiökokous | 12.5. | |
| 2025 Q1-osavuosiraportti | 8.5. | |
| 2024 Q4-osavuosiraportti | 21.2. | |
| Merkintäoikeusanti | 3.1. |
Datan lähde: Millistream, Quartr
Q2-osavuosiraportti
24 päivää sitten‧34 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q3-osavuosiraportti | 14.11. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 19.8. | |
| 2024 Yhtiökokous | 12.5. | |
| 2025 Q1-osavuosiraportti | 8.5. | |
| 2024 Q4-osavuosiraportti | 21.2. | |
| Merkintäoikeusanti | 3.1. |
Datan lähde: Millistream, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 7.9.·AcuCort expands the organization with Business Development Director according to Linkedin https://cvformat.io/blog/business-development-director-job-overview
- 28.8.·New orders, letters of intent and regulatory progress in interaction https://analystgroup.se/analyser/acucort-q2-25/
- 22.8.·Now the sales need to get going in earnest. However, it seems that there is a lack of information for doctors. Especially in general practice, there has been no information that the product is on the market. So GPs cannot prescribe it if they do not know the product exists. Bad, very bad PR…
- 19.8. · Muokattu·There is a webcast about Q2 at 11am today, no registration required. There will be an opportunity to ask questions. https://www.youtube.com/live/sWHfe7XqRK819.8.·It sounds very good, if it weren't for the very boring/weak sales figures of 162 thousand kroner in the first half of the year. I still think it could be good, but my investment is based on hope and that I like that the product and company are simple - I don't think the numbers and the development speak much for it so far.
- 19.8.·AcuCort publishes interim report for the second quarter of 2025 https://www.acucort.se/sv/acucort-publicerar-delarsrapport-for-andra-kvartalet-2025/19.8.·Acucort reports loss as expected - ongoing discussions with potential partners today at 08:40 ∙ Finwire Smallcap Life science company Acucort increases sales and losses in the second quarter. Revenue amounted to SEK 0.2 million (0). Operating profit was SEK -7.6 million (-3.8). Profit after tax was SEK -7.6 million (-3.8). Earnings per share were SEK -0.03 (-0.05). Cash and cash equivalents at the end of the period were SEK 32.4 million. "The second quarter of 2025 has been marked by clear and important steps forward in our international expansion. In May and June, we signed two strategic letters of intent regarding distribution agreements. The first was with Lunatus for the Middle East and the Gulf States and the second with Glenmark Pharmaceuticals for Germany and five additional European countries," CEO Jonas Jönmark says in the report. He is also raising the issue with the FDA regarding the iPSP application. "The FDA's response to our iPSP application was scheduled for the first quarter, but the process has been delayed due to internal organizational challenges at the agency. We have finally received their response and are now working to answer a number of questions that have been raised," says Jönmark. The Acucort CEO continues. "Looking ahead, we see several exciting opportunities. Our ongoing discussions with potential partners in both Europe and other parts of the world have intensified. At the same time, important efforts are underway in the regulatory area to secure long-term market access and build clinical credibility in all relevant markets."
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market SE
Määrä
Osto
16 601
Myynti
Määrä
43 471
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 171 | NRD | NON | ||
| 7 600 | NRD | AVA | ||
| 16 129 | AVA | NRD | ||
| 1 000 | AVA | NRD | ||
| 3 539 | AVA | NRD |
Ylin
0,58VWAP
Alin
0,556VaihtoMäärä
0,2 327 655
VWAP
Ylin
0,58Alin
0,556VaihtoMäärä
0,2 327 655
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Svenska Handelsbanken AB | 90 000 | 6 000 | +84 000 | 0 |
| Nordnet Bank AB | 100 191 | 72 892 | +27 299 | 5 000 |
| Carnegie Investment Bank AB | 7 128 | 0 | +7 128 | 0 |
| Skandinaviska Enskilda Banken AB | 32 | 0 | +32 | 0 |
| Nordea Bank Abp | 10 338 | 63 400 | −53 062 | 0 |
| Avanza Bank AB | 119 966 | 185 363 | −65 397 | 38 391 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Avanza Bank AB | 119 966 | 185 363 | −65 397 | 38 391 |
| Nordea Bank Abp | 10 338 | 63 400 | −53 062 | 0 |
| Skandinaviska Enskilda Banken AB | 32 | 0 | +32 | 0 |
| Carnegie Investment Bank AB | 7 128 | 0 | +7 128 | 0 |
| Nordnet Bank AB | 100 191 | 72 892 | +27 299 | 5 000 |
| Svenska Handelsbanken AB | 90 000 | 6 000 | +84 000 | 0 |